|

Rituximab Biosimilar Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: RIABNI®, RUXIENCE®, TRUXIMA®

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Merck Sharp & Dohme LLC2

Indications

  • Cancer2
  • Lymphoma, Large B-Cell, Diffuse1
  • Diffuse Large B-Cell Lymphoma1

Mobile, Alabama1 trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Infirmary Cancer Care ( Site 0157)

Phase 2

Gilbert, Arizona1 trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Banner MD Anderson Cancer Center ( Site 0165)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.